Autologous bone marrow transplantation (ABMT) after high-dose chemotherapy is recognized as a curative approach to treating hematologic malignancies and some invasive solid tumors. However, tumor cells present in the bone marrow at the time of harvesting are a potential cause for relapse. Ex vivo marrow purging with very high doses of cytotoxic agents has been introduced in an attempt to remove neoplastic cells contaminating the autograft. The procedure, however, has been limited by its high toxicity to normal bone marrow progenitor cells. In their purging procedures, investigators have used agents such as amifostine, originally developed to protect against the effects of radiation and chemotherapy. In this article, the appropriateness of protecting normal cells with amifostine during various purging procedures will be reviewed.
ment-related complications limit the usefulness of the procedure. Autologous bone marrow transplantation (ABMT) and peripheral blood stem cell (PBSC) reinfusion 2 have emerged as alternative approaches for the treatment of hematologic malignancies and selected tumors that respond to dose-escalation therapy. There is clear evidence of the clinical benefits of high-dose therapy with ABMT for the treatment of acute leukemias, [3] [4] [5] [6] [7] non-Hodgkin's lymphoma, [8] [9] [10] [11] Hodgkin's disease, 10 multiple myeloma, 12 breast cancer, [13] [14] [15] and germ cell carcinoma of the testes. 16 Studies examining ABMT or PBSC reinfusion are also underway for patients with chronic myelogenous leukemia [17] [18] [19] and neuroblastoma. 20 Although treatment-related complications are less likely to arise with ABMT than with alloBMT, ABMT suffers from two drawbacks that may be responsible for the higher relapse rate seen with this procedure. The first results from the absence of graft-versus-host disease (GVHD). Attempts to eradicate GVHD have resulted in a high tumor relapse rate, indicating that a component of 'graft-versus-tumor' may be essential for eradicating malignant cells that survive high-dose preparative treatment. 21, 22 Therefore, while the complications of graft-versus-host reaction are absent in autografting, so are the potential beneficial effects of this reaction. The second drawback, contamination of harvested bone marrow with tumor cells, is well recognized in hematologic malignancies, and is also common in some solid tumors that have metastasized to the bone marrow, including breast cancer, 23, 24 non-small cell lung cancer, 25 and gastric and colon malignancies. 23, 26, 27 In this review, we explore the attempts that have been made to purify contaminated marrow using purging procedures before reinfusion and the efforts currently underway to enhance the efficacy of these procedures while protecting normal progenitor cells.
Bone marrow purging
While high-dose therapy with autologous marrow support can achieve increased response rates and tumor-free survival, disease relapse is still the major cause of treatment failure. In theory, relapse can be due to inefficient eradication of systemic disease or to reinfusion of tumor cells with the autograft. The relative contribution of these two factors remains controversial. Data from syngeneic transplants indicate that a large portion of relapses are due to residual systemic disease. Gene-marking experiments, on the other hand, have clearly demonstrated that tumor cells contaminating the grafted bone marrow can contribute to tumor recurrence in leukemia 28 and solid tumors. 29, 30 In a study conducted by Brenner et al, 28 bone marrow cells harvested from two patients with acute myelogenous leukemia were transduced prior to implantation with a retroviral vector harboring a copy of the neo r gene. Both patients relapsed. In both cases, selected gene-marked cells (assessed according to their resistance to the neomycin analogue G418) were found to contribute to the population of malignant cells in the recurrent tumor. In another study, marrow harvested from eight patients with neuroblastoma in clinical remission was transduced with neo r -containing retroviral vector and reinfused as part of the ABMT. 29 Genetically marked cells contributed to the tumor cell population in the three patients who relapsed. Analysis of DNA from selected and amplified neuroblasts indicated that in each patient at least 200 clonogenic tumor cells were infused with the marrow and contributed to relapse.
Procedures have been devised to remove contaminating tumor cells from the autograft material and reduce risk of relapse after ABMT. These procedures are commonly referred to as purging. Chemical (pharmacological) and immunologic methods are used most frequently. 31 A key to the success of the purging method is the selective cytotoxicity of the purging agent -ie its ability to kill tumor stem cells rather than normal marrow progenitor cells. Toxicity to normal marrow progenitor cells can be assessed by quantification of the proportion of residual viable granulocyte-macrophage colony-forming units (CFU-GM) remaining in the marrow suspension after the purging procedure. 32, 33 An inverse relationship between the percent of viable CFU-GM and the time to engraftment has been demonstrated. 34 Chemical purging to eliminate leukemic cells from suspensions of normal bone marrow has been studied extensively since the initial report by Sharkis et al. 35 Protocols for pharmacologic marrow purging have relied on the incubation of 10 7 mononuclear cells/ml with either 50 g/ml mafosfamide 3, 36 or 80 g/ml 4-hydroperoxycyclophosphamide (4-HC). 33 Even though cyclophosphamide derivatives used in purging selectively target tumor cells, the toxicity associated with these agents results in the destruction of more than 95% of late progenitor cells 37, 38 and is sometimes accompanied by delayed engraftment or failure to engraft, 39 especially in patients with AML.
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Clinical outcome and purging efficacy Randomized studies: To date, no randomized studies have examined the clinical benefit of marrow purging. Such studies are relatively difficult to construct because of the high incidence of disease relapse even when no tumor cells are infused in the marrow. One author estimated that over 1000 patients would have to be randomized in order to detect, with statistical confidence, the clinical benefit of graft purging. 41 Some authors have pointed out, however, that genemarking techniques may be helpful in clinical trials assessing the efficacy of methods used for marrow purging. The endpoint of such studies would be the absence of marked cells in relapsed tumor rather than the rate of relapse; therefore, even studies enroling small numbers of patients would provide adequate information on the efficacy of the purging procedure. 28 One randomized study has been initiated, however. The NHL-European CUP trial will compare the efficacies of conventional chemotherapy, high-dose therapy with purged autografting, and high-dose therapy with unpurged autografting for treatment of poor-risk, relapsed NHL. 31 Controlled studies: Several studies that correlated in vitro purging efficacy with postengraftment clinical outcome have suggested a benefit from autograft purging. In one study of mononuclear bone marrow cells from leukemic patients the sensitivity of leukemia colony-forming units (CFU-L) and granulocyte-macrophage colony-forming units (CFU-GM) to varying doses of 4-HC was correlated with clinical outcome after transplantation of the purged marrow. 42 Miller and colleagues successfully cultivated in vitro CFU-L obtained from 45 out of 58 patients in complete response before transplantation of purged marrow. A comparison of the sensitivity of CFU-L and CFU-GM to 4-HC revealed that CFU-L could be classified as either more sensitive or more resistant than CFU-GM to 4-HC, whereas the sensitivity of CFU-GM remains constant. Multivariate analyses suggest that only the sensitivity of CFU-L to the purging agent correlated with clinical outcome, and that the probability of relapse was only 18% in patients whose CFU-L were sensitive to 4-HC, and 77% in patients with resistant CFU-L (P Ͻ 0.0001). It should be noted that the same class of agents (cyclophosphamide derivatives) was used for the preparative regimens and for ex vivo graft purging in this study. Therefore, marrow with resistant leukemic cells may have been harvested from patients in whom the preparative regimen did not completely eradicate disease. Higher relapse rate in these patients may be due either to inadequate purging or to the presence of resistant residual systemic disease.
The most compelling data supporting the clinical usefulness of ex vivo marrow purging was provided by Gribben et al, 43 who examined the efficacy of purging bone marrow from patients with B cell non-Hodgkin's lymphoma. The study involved 114 patients whose lymphoma cells exhibited PCR-identifiable translocation of the bcl-2 gene. Bone marrow samples were analyzed for the presence of tumor cells before and after the purging procedure. Harvested marrow from all patients was found to contain malignant cells and was exposed to three cycles of immunological purging. Tumor cells were successfully depleted below the levels of PCR detection in the marrow from 57 patients. Only four patients (7%) from this group relapsed, compared with 26 (46%) from the group that was transplanted with the marrow that remained PCR-positive after purging (P Ͻ 0.00001).
Studies correlating purging efficacy with clinical outcome are often criticized because some feel that the efficacy of purging depends on the original tumor load and resistance to preparative regimens. Under these conditions, inadequate purging simply reflects inadequate eradication of systemic disease. While such criticism is well founded for procedures using the same class of cytotoxic agents for purging and for systemic preparation, 42 it is not clear that there is a relationship between drug resistance and resistance to immunological purging. For instance, in the Gribben study, 43 tumor burden was not a prognostic factor for purging efficacy. Additionally, patients whose marrow was successfully purged and those whose marrow remained contaminated showed similar responses to induction or salvage chemotherapy, indicating a lack of correlation between sensitivity of malignant cells to chemotherapy and efficacy of immunological purging.
In a study by Rowley et al, 44 purging efficacy was assayed using CFU-GM survival as a surrogate marker. Bone marrow harvested from 45 patients with AML was purged with 4-HC, and the purging efficacy was measured as elimination of CFU-GM. Cytotoxicity of the purging regimen strongly depended on the red blood cell content of the purged marrow. Patients whose marrow was judged to be adequately purged (CFU-GM survival Ͻ1%) had fewer relapses (P = 0.01) and longer disease-free survival (P = 0.006) than did those transplanted with less effectively purged marrow. Additionally, there was no correlation between purging efficacy and systemic disease burden.
The study implies that the leukemic cells present in the autograft contribute to disease relapse, but also that patients undergoing ABMT can benefit from adequate purging procedures. Alternatively, the procedure used to assay purging efficacy may reflect the intrinsic sensitivity of leukemic cells to preparative drug treatment, and therefore low purging efficacy is indicative of residual disease. In this study, however, the efficacy of purging was highly dependent on extrinsic factors (red blood cell content of the marrow), and a surrogate marker (CFU-GM elimination) was used to define the toxicity of the purging procedure. As there does not appear to be any intrinsic difference in CFU-GM drug sensitivity between different groups of patients, 42 the observed variability seems to reflect only the cytotoxicity of the purging procedure itself, and the probability that this surrogate marker reflects the efficacy of systemic preparative regimens is low.
Retrospective studies: The results of several retrospective studies indicate that bone marrow purging with a cyclophosphamide derivative may provide clinical benefit. In a European Cooperative Group for Bone Marrow Transplantation (EBMT) study, the records from 919 patients who received ABMT for treatment of AML 45 confirmed this benefit in patients receiving total-body irradiation and in all CR1 patients who were followed-up for at least 2 years (relapse rate, 35 vs 47%, P = 0.04). Only 29% of CR1 patients receiving mafosfamide-purged marrow after TBI relapsed, whereas relapse occurred in 50% of those receiving unpurged marrow (P = 0.005).
In a study by the Italian Mafosfamide Study Group, 125 patients with AML were autografted with either unpurged bone marrow (n = 87), bone marrow purged with standarddose mafosfamide (n = 21), or marrow purged with mafosfamide at a dose adjusted for the sensitivity of leukemic cells to the drug (n = 17). 4 Patients who received unpurged marrow relapsed at a significantly higher rate (54%) than did those who received adjusted-dose purged marrow (32%, P = 0.0084). Patients who received bone marrow that was purged with standard-dose mafosfamide relapsed at an intermediate rate (43%). This study indicated that adjusting the intensity of purging according to leukemic cell sensitivity to the purging agent can benefit engrafted patients significantly.
Purging issues
Purging has often been criticized as unnecessary, and the clinical utility of purging is still controversial. Some investigators argue that the high incidence of relapse occurring even when no tumor cells are reinfused with the marrow indicates that only when the induction therapy is successful enough to leave the patient with a small tumor burden, is BMT conditioning sufficient to eliminate all residual tumor cells, implying that purging of the graft is probably unnecessary. Additionally, even when a clinical benefit from pharmacologic purging can be demonstrated, toxicity of the purging agent to normal marrow progenitor cells is defined as a major limitation because an inverse relationship between the percentage of viable CFU-GM and the time required for successful engraftment has been demonstrated. Patients with hematologic malignancies (n = 35) and pediatric solid tumors (n = 5) undergoing ABMT with marrow that was purged using 100 g/ml 4-HC were shown to have similar numbers of CFU-GM prior to the purging step. However, the recovery of CFU-GM after purging ranged from 0.07 to 23%, and the time to engraftment for leukocytes (у1000/l), granulocytes (у500/l), reticulocytes (у2%), and time to the last platelet transfusion were linearly correlation with the log of the CFU-GM content after purging. 34 Similar results were reported for 25 patients with metastatic breast cancer undergoing ABMT with bone marrow that was purged with escalating doses of 4-HC (20 g/ml to 80 g/ml). 32 Colonies derived from CFU-GM were scored before and after the purging procedure. The time to engraftment (leukocytes у1000/l) was strongly correlated with the log of the CFU-GM marrow content after purging (P = 0.0005). Recovery of CFU-GM after the purging procedure depended on the dose of 4-HC used for purging and ranged from 4.5% for the 8 g/ml dose (n = 8) to 80% for the 20 g/ml dose (n = 4). Time to engraftment was also dose-dependent, requiring 28 days at the highest 4-HC dose level and 19 days at the lowest (P = 0.027). The mean time to engraftment in patients who had received unpurged marrow in the same institution (historical controls, n = 22) was 17 days. These studies indicated that cytotoxicity of the purging agent may lead to prolongation of hospitalization, and an increased need for blood and platelet transfusions.
Additional investigations revealed that the efficacy of the purging procedure is correlated with a positive clinical outcome for patients undergoing ABMT but results in a prolonged time to successful engraftment. In one study, patients with AML who achieved continuous remission after ABMT had a lower percentage of CFU-GM survival (1.1%) and longer periods of aplasia (53 days), than did those in relapse (4.2%, P = 0.06, and 31 days, P = 0.03, respectively). 44 Similarly, in a more recent phase II study, patients with AML who underwent transplantation with purged marrow experienced a lower relapse rate (28 vs 62%), but had longer times to engraftment (31 vs 23 days) than did those infused with unpurged marrow. 6 These studies suggest that to maintain clinically effective purging without unacceptable delays in engraftment, may require reduction of cytotoxicity to the normal marrow progenitor cells, and some believe that purging may be useful only if it does not harm the bone marrow or result in unacceptable delays in engraftment. 41, 46 The issue of acceptability of purging procedures is further complicated by recent reports of a hierarchy among leukemic cells suggesting that the primitive progenitors are the site of leukemic transformation. 47, 48 The heterogeneity of leukemic blasts with respect to their ability to proliferate has been demonstrated with severe combined immunodeficient (SCID) mice engrafted with marrow cells from CML patients in chronic phase or in myeloid or lymphoid blast crisis, 49 and with suspension culture and long-term culture initiating cell assays (SC-IC and LTC-IC, respectively). 48 These findings are consistent with the data by Miller et al 42 which demonstrated that the variation in sensitivity to the purging agent of CFU-L clones established from patients correlated with clinical response. Whereas this realization suggests that the dose of purging agent should be tailored to the sensitivity of the leukemic clone, 50 it has been established that LTC-IC of primitive leukemic stem cells are less sensitive to mafosfamide than are late progenitors. 51 Consequently, it is probably sufficient to limit cytoprotective measures initially to late progenitors, which are most affected by the purging treatment. Since it is essential to provide faster engraftment by maintaining a viable population of normal precursors such as CFU-GM, it is justified to extend cytoprotective measures to late progenitors only to favor a dose increase that can eliminate more primitive leukemic precursors. Protecting normal marrow progenitor cells from the cytotoxicity of the purging agent may provide the required level of safety to make this procedure more acceptable and clinically beneficial to patients with advanced cancer.
Cytoprotection in purging procedures
A number of agents have been developed that confer protection to normal tissue against the effects of radiation or chemotherapeutic regimens used to treat cancer in humans, or to rescue normal tissue after therapy-induced damage has occurred. These include sulfhydryl agents; 52,53 chelating agents; 54 a variety of cytokines and growth factors such as interleukin 1 (IL-1), IL-3, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor; 55 and an acetylated tetrapeptide: AcSDKP (goralatide, seraspenide). 56 Among these agents, AcSDKP has shown some effectiveness in protecting normal CFU-GM progenitors during hyperthermic purging procedures in the preclinical setting, 57 and amifostine has been clinically evaluated in the ABMT setting and may hold promise for developing more acceptable and efficacious purging procedures.
Amifostine-based purging in hematologic malignancies
Amifostine (WR-2721; Ethyol) is a phosphorylated aminothiol compound that was originally developed as a radioprotective agent. 52, 58, 59 Since then, it has been found to selectively protect normal bone marrow cells from chemotherapy-and radiotherapy-induced cytotoxicity while the antitumor effectiveness of the therapy appears to remain intact. 33, [59] [60] [61] [62] [63] [64] [65] [66] Amifostine is a pro-drug because its mechanism of action requires conversion by alkaline phosphatase to the active free thiol compound, WR-1065. Recent studies suggest that WR-1065 is selectively taken up into normal cells by a high affinity mechanism. 67 However, amifostine is less readily transported across the membranes of tumor cells, suggesting a diffusion mechanism in these tissues. 61 Additionally, owing to structural similarities with nuclear polyamines, amifostine is compartmentalized in the vicinity of DNA and appears to confer protection against mutagenic toxins.
Early studies in AKR mice and the corresponding AKR leukemia demonstrated that amifostine pretreatment clearly protected spleen colony-forming units (CFU-S) from the toxicity of nitrogen mustard. There was no protection of AKR leukemia cells, and the cytotoxic effects of nitrogen mustard on leukemia cells were paradoxically enhanced. At a nitrogen mustard dose of 0.3 mg, amifostine pretreatment resulted in a 100-fold increase in protection of CFU-S and a 100-fold enhancement of leukemic cell kill. 68 More recently, amifostine was shown to protect effectively the proliferative activity of normal hematopoietic colony-forming unit cells such as CFU-GM, erythroid CFU (CFU-E), and CFU-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) exposed to 4-HC or other agents used in bone marrow purging regimens to treat acute lymphoblastic leukemia (ALL). Conversely, ALL cell lines incubated for up to 5 h with 4-HC received no protection from amifostine. 69 The ability of amifostine to selectively protect healthy bone marrow progenitor cells vs leukemic progenitor cells from the cytotoxic effects of mafosfamide has been evaluated in human subjects. 38 The dose response of leukemic cells and normal marrow progenitor CFU to mafosfamide and amifostine has been determined, and the dose that was lethal to 95% of cells (LD 95 ) has been calculated. Although it could be argued that a better measurement of the survival of CFU-L after mafosfamide in the presence of amifostine should be assessed at a maximally effective purging dose (уLD 99 ), LD 95 appears more appropriate because it provides sufficient cell survival to achieve successful engraftment of the purged marrow. At a lethal dose resulting in 95% CFU-L cell kill, amifostine pretreatment resulted in statistically significant protection of both late myeloid progenitor cells such as CFU-GM and of normal erythroid progenitor cells such as erythroid burst-forming units (BFU-E) from the toxicity of mafosfamide (P = 0.031), demonstrating that the mafosfamide LD 95 is raised in ex vivo purging procedures when amifostine is used to protect normal marrow progenitor cells. In addition, amifostine pretreatment increased the cytotoxicity of mafosfamide to human leukemic cells (P = 0.006). 38 A recent study shows that both amifostine and WR-1065 protect bone marrow progenitor cells obtained from normal donors against the cytotoxicity induced by a variety of chemotherapeutic agents. 70 Compared with controls, amifostine enhanced the colony-forming capacity of CFU-GEMM by 1.29-, 1.56-and 9.57-fold in the presence of daunorubicin, paclitaxel and mitoxantrone, respectively, but did not afford protection against cisplatin, diaziquone or thiotepa. Amifostine also protected BFU-E, enhancing by 1.35-, 2.09-, 2.34-, 3.39-and 64.68-fold their colony-forming capacity in the presence of diaziquone, cisplatin, paclitaxel, doxorubicin and mitoxantrone, respectively; WR-1065 provided less protection. This broad hematoprotection appears to stem from inherent trophic effects on progenitor growth. 71 Accordingly, recent studies demonstrate that amifostine can stimulate growth of CD34 + cells that exceeds progenitor growth initiated with IL-1 or IL-3 in both normal and myelodysplastic bone marrow. 70 This effect is attributed to the ability of amifostine to stimulate the maturation of preleukemic AML and CML cells and prevent the proliferation of immature cells. 72 This may be highly important in view of the documented resistance of early leukemic progenitors to mafosfamide treatment. 51 A recent phase I/II clinical trial indicated that patients with myelodysplastic syndrome may benefit from amifostine treatment with an absolute increases in the myeloid progenitors CFU-GEMM experienced in 80% of patients, BFU-E in 53%, and CFU-GM in 40%. 73 The apparent dual effect of amifostine protection of normal marrow progenitor cells coupled with amifostineinduced maturation of leukemic cells results in an increased potential for leukemic cell eradication. Combined amifostine pretreatment and mafosfamide treatment at the LD 95 concentration established for marrow progenitor cells results in an estimated increase of six orders of magnitude in leukemic cell eradication. 38 Before firm conclusions are drawn from these experiments, however, it is desirable to gather additional support from experimental models more relevant to human leukemia.
These studies demonstrate the potential for preserving a greater number of normal stem cells for autologous transplantation while lowering the incidence of leukemic relapse. Because grafts utilizing PBSC result in a lower rate of treatment-related complications, purging techniques adapted to these cells are currently under investigation in our laboratory, in addition to bone marrow purging studies.
Amifostine-based purging for metastasized solid tumors
In addition to the studies by Shpall et al 32 previously mentioned amifostine has been shown to protect selectively human CFU-GM progenitor cells from the cytotoxic effect of 4-HC without altering its cytotoxic effect on human breast cancer cells contained in the same bone marrow suspension. 33, 74 In vitro experiments intended to mimic actual purging conditions, with a mixture of normal human bone marrow and 10% human breast cancer cells, demonstrated selective cytoprotection of normal cells with amifostine. 74 In this setting, amifostine provided a 10-fold increase in CFU-GM survival but no protection of breast cancer cells from 4-HC toxicity. Assay of residual CFU-GM following purging with 4-HC (with or without amifostine pretreatment), before ABMT in patients with breast cancer or NHL resulted in a 100-fold higher number of viable CFU-GM in the marrow pretreated with amifostine compared to that treated with 4-HC alone. This significantly shortened the time to marrow recovery, or engraftment, reducing the risk of complications related to myelosuppression. Consequently, there was a decreased need for supportive care measures such as platelet and red blood cell transfusions. 74 
Photodynamic purging
In a recent in vitro study, the effectiveness of light-activated merocyanine 540 phototreatment (LAMP) as a means of purging small cell lung cancer (SCLC) cells from human bone marrow was tested in the presence of amifostine to protect normal CFU cells. 75 In the absence of amifostine, light exposure intervals of up to 120 min substantially reduced the number of both SCLC cells and pluripotent hematopoietic progenitors, CFU-GEMM, CFU-G, CFU-M and CFU-E. During a 60-min phototreatment of normal bone marrow containing 1% or 5% SCLC cells, amifostine pretreatment protected CFU, but not SCLC cells. This demonstrated that amifostineassisted LAMP fulfilled the requirements of a successful purging method by completely eliminating SCLC cells while sparing hematopoietic cells associated with marrow reconstitution.
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Conclusion
A number of techniques are currently in use to replenish bone marrow contaminated by neoplastic cells or impaired by chemotherapeutic agents or radiation therapy. Although techniques such as peripheral blood progenitor mobilization and harvest for autografting have produced interesting results, providing effective stem cell support, the techniques still result in the presence of residual neoplastic cells. Likewise, techniques using photoactive agents are still highly experimental. ABMT after high-dose chemotherapy has emerged as a curative approach for certain malignancies, such as AML, ALL, and solid tumor metastases to the bone marrow. Ex vivo purging of bone marrow with 4-HC and mafosfamide has been used to remove residual neoplastic cells that contaminate bone marrow autografts, thus reducing the incidence of relapse; these techniques may be adaptable to engraftment procedures using PBPC. A major limitation of the purging procedure, however, is the cytotoxic effects of chemotherapeutic agents on the normal bone marrow progenitor cells that are responsible for marrow engraftment.
Amifostine selectively protects normal bone marrow cells from the toxicity of alkylating agents and photoactive agents without interfering with their antitumor activity. In addition, amifostine pretreatment may increase the cytotoxicity of mafosfamide on human leukemia progenitor cells and/or stimulate preleukemic cell maturation. This combination of normal cell protection and potential preleukemic stem cell maturation may preserve a greater number of nor-mal stem cells for autologous transplantation while lowering the incidence of leukemic relapse.
Whereas significant cytoprotection and improved bone marrow progenitor cell recovery with enhanced purging efficacy has been demonstrated, issues concerning effective eradication of primitive leukemic cells remain and must be addressed to widen the indications for bone marrow purging procedures.
